New injection shows promise for lowering cholesterol in indian patients

NCT ID NCT06386419

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the safety and effectiveness of inclisiran sodium, a cholesterol-lowering injection, in 65 Indian adults with high cholesterol or mixed dyslipidemia. Participants received three doses over 270 days. The goal was to see how well it lowers LDL cholesterol and if any side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inclisiran sodium
What this could lead to: If successful, this could confirm that inclisiran is a safe and effective option for lowering cholesterol in Indian patients, offering a convenient injection schedule.
What could go wrong: This is a small, completed Phase 4 study with only 65 participants, so results may not apply to everyone. Side effects or lack of effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIXED DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia, familial combined, LPL related

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIXED DYSLIPIDEMIA PRIMARY HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Novartis Investigative Site

Bangalore, Karnataka, 560099, India
Novartis Investigative Site

Belagavi, Karnataka, 590010, India
Novartis Investigative Site

Mumbai, Maharashtra, 400012, India
Novartis Investigative Site

Nagpur, Maharashtra, 441108, India
Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, 110029, India
Novartis Investigative Site

Jaipur, Rajasthan, 302039, India
Novartis Investigative Site

Madurai, Tamil Nadu, 625107, India
Novartis Investigative Site

Vellore, Tamil Nadu, 632 004, India
Novartis Investigative Site

Kolkata, West Bengal, 700 020, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.